Funding for this research was provided by:
Foundation for a Smoke-Free World (W1-55)
Text and Data Mining valid from 2020-03-02
Received: 6 November 2019
Accepted: 11 February 2020
First Online: 2 March 2020
Ethics approval and consent to participate
: No ethical approval or participant consent was required.
: Not applicable.
: MG has in the distant past (over 10 years ago) consulted to pharmaceuticals companies on NRT, Zyban, and Champix. MG has never received funding from tobacco companies or vaping products companies. CVP is an advocate of tobacco harm reduction and for promoting a better understanding of the uncertainty inherent in epidemiologic studies. Over the course of his career, he has received both research grants and consulting funding from producers of every one of the products mentioned in this review except iq’mik (most focused on issues related to tobacco harm reduction), as well as employment as a consumer advocate promoting tobacco harm reduction and very modest consulting income specifically related to birth outcomes and smoking.